Get Ready, Traders!
Citius Pharmaceuticals (CTXR) is the stock I want the Posse stalking tomorrow morning. I get the hunch this one's going to be UNIQUE!
If you snooze through this one, I got no sympathy and ZERO excuse. We may NEVER see this combination of factors here again!
We talked last night about the no-nonsense drug pipeline CTXR has already taken into Phase 3, the last trial before the FDA says yes or no.
Pipeline like that, clinical news flow like that, a lot of traders might think we were looking at Big Pharma, something established and global in scope.
Heck, CTXR has that kind of effect on people. A lot of the other headlines here look more like a Fortune 500 operation than the typical OTC mite.
Let's get that chart up and then I'll fill you in on the rare combo plate we're eating from here:
Start with the management team. I mentioned last night that the top names on the org chart are not only high-powered but deeply invested.
The CEO is from Roche Labs. There's a pedigree to conjure with in the pharma world right there, right?
The chairman is something else entirely. He came to CTXR after getting merged into the company a little while back.
Turns out he's so stoked to be there that he's poured $3 million more of his own cash into the company -- over and ABOVE the merger shares.
That's a HUGE insider signal on a company of this size, not to mention the 7-digit vote of confidence! If I had that cash, would I do it?
All I really know is that he's in star company. The rest of the board have titles like "company group chairman, Johnson & Johnson" on the resume.
Then there's the Duke medical professor, who ran a hospital for 2002-3 and a couple of start-up companies on the side.
And then there's the ex-New York City police commissioner, who was also assistant director of the DEA and also ran a couple companies.
High-powered crowd. They don't waste their time. So if CTXR isn't performing ahead of the curve, guess what? They'll make changes.
And I get a STRONG feeling that they want to ramp this baby to the moon as FAST as the clinical calendar allows!
As it is, CTXR turnover over the last month is roughly what it printed the rest of the year put together. We're looking at a flood of action forming here.
I talked technical last night, so look up that email if you want some trend discussion. For today, let's just say reversion to mean is our friend.
But if a drug trial actually finishes on our watch, the impact could be truly exponential. You know how the "binary catalysts" work in Big Pharma!
The lead contender here is a drug that’s already at Phase 3, which is the last step before FDA review for actual medical use.
Like I said last night, it ain’t sexy. It lets hospital patients keep a central line longer than the 6 days when they start to get infected.
I dunno if you’ve ever been in the ICU, but these direct feeds into the chest are a godsend, pumping life-giving drugs straight into the body.
Keeping the lines clean can save about 1/3 of patients from miserable infection and expensive complications if not death.
If CTXR can do that, the Centers for Disease Control will basically award a medal. And with so many procedures getting done, there’s revenue here.
Then there’s the follow-up program, an improved hemorrhoid cream already at Phase 2. I didn’t say it was sexy, but again, big revenue potential here!
How often do you see a real drug company with Phase 3 trials in our world? This ain’t no 3-digit biotech giant . . . it’s GROUND FLOOR!
Happy, Happy, Happy Trading!
~ Stock Commander
yourstockcommander@gmail.com
